New York Cannabis Sales Top $1.4 Billion Through Q3

MJBizDaily puts New York's legal market past $1.4 billion

New York's legal cannabis sales topped $1.4 billion through the third quarter, according to an Oct. 28 MJBizDaily report.

That headline is the verified core of this story. The underlying dataset, the reporting window and the category split weren't part of the signal we reviewed.

So we'll stick to what the number supports. It's a scale marker for the New York market, and a useful one. It isn't an earnings print.

The run-rate math behind the headline

Spread evenly over nine months, $1.4 billion works out to about $156 million in sales per month.

Here's the arithmetic, which is ours and not MJBizDaily's. It assumes the figure covers January through September.

• About $467 million per quarter on a straight-line average.
• About $156 million per month ($1.4 billion divided by nine).
• Roughly $1.87 billion annualized if the pace simply holds.

Straight-lining is crude. Markets that are still adding licensed storefronts rarely sell at a flat monthly pace, so the exit rate could sit well above the average, or it could sit below it. Without monthly data, nobody can say which.

What the headline doesn't tell us

Several variables decide whether $1.4 billion is a strong number, and none of them are in the signal.

Treat the figure as incomplete until these are answered:

1. Period definition. Is it calendar year-to-date, a fiscal window, or a cumulative total? If it's cumulative, the run-rate math above collapses.
2. Data source. The Office of Cannabis Management (OCM) regulates the market, but the signal doesn't say where the sales figure originated.
3. Price versus volume. Revenue can rise while unit sales stall if prices climb, and the reverse is just as likely. Headline dollars hide that split.
4. Tax treatment. We don't know whether the total is pre-tax or includes excise and sales taxes.

Each one swings the read. Ignore them and you're reading a press-release number.

The operator and investor lens: revenue isn't margin

For licensed operators, top-line growth in New York matters only as far as it survives price compression and the tax burden.

Cannabis companies still run under Section 280E of the federal tax code, which bars ordinary business deductions for trafficking in Schedule I or II substances. Effective tax rates can swamp reported gross profit. A $1.4 billion market can still be a hard place to make money.

Investors in multistate operators (MSOs) should watch the metrics that sit under the headline: same-store sales, average transaction size and gross margin in basis points. A market growing 20% with margins falling 300 basis points can be a net negative for a single operator's EBITDA. That math is hard to argue with.

Our read: a nine-month total tells you the size of the pie, not how many players are splitting it or how thin the slices are getting.

Patients and consumers get a different read. A larger legal market generally means more storefronts competing for them, though the signal gives no store count to confirm it.

What to watch next

The next useful data points are monthly sales cadence, Q3 operator filings and any OCM release that breaks out categories.

Public companies with New York exposure will report Q3 results in coming weeks. Their 10-Q segment disclosures will show whether the state is lifting revenue per location or just adding locations. Compare that against the state-level total.

For full background on how the market got here, see the CannIntel topic hub on the New York cannabis rollout. Other states, including California and Ohio, offer useful comparisons on how fast a young market's growth curve flattens.

The next signal: a full-year 2026 total, which will show whether the $156 million monthly average was a floor or a ceiling.